Navigation Links
Main Street Capital Announces New Portfolio Investment
Date:9/14/2011

HOUSTON, Sept. 14, 2011 /PRNewswire/ -- Main Street Capital Corporation (NYSE: MAIN) ("Main Street") announced today that it has completed a new lower middle market portfolio investment totaling approximately $6.8 million in invested capital.

The investment was made to support the acquisition of the assets and business of a dedicated investigative facility (the "Company"), which conducts clinical trials for the pharmaceutical industry, by a group of private investors. Main Street's investment consists of $6.3 million in first lien secured debt and a $0.5 million direct equity investment.

Staffed by physicians and support personnel, the Company recruits and treats patients with later stage drugs in development by its pharmaceutical company clients. The Company's primary focus is on Phase II and Phase III metabolic disease trials, principally in diabetes, hypertension and obesity. The Company is headquartered in California.

ABOUT MAIN STREET CAPITAL CORPORATION

Main Street (www.mainstcapital.com) is a principal investment firm that primarily provides long-term debt and equity capital to lower middle market companies. Main Street's lower middle market investments are made to support management buyouts, recapitalizations, growth financings and acquisitions of companies that operate in diverse industry sectors and generally have annual revenues ranging from $10 million to $100 million.  Main Street seeks to partner with entrepreneurs, business owners and management teams and generally provides "one stop" financing alternatives within its lower middle market portfolio. Main Street also maintains a portfolio of privately placed, interest-bearing debt investments in middle market businesses that are generally larger in size than its lower middle market portfolio companies.

Contacts:
Main Street Capital Corporation
Dwayne L. Hyzak, Chief Financial Officer and Senior Managing Director
dhyzak@mainstcapital.com
713-350-6000

Dennard Rupp Gray & Lascar, LLC
Ken Dennard  |  ksdennard@drg-l.com
Ben Burnham |  bburnham@drg-l.com
713-529-6600


'/>"/>
SOURCE Main Street Capital Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
2. Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010
3. Water Street Healthcare Partners Signs Definitive Agreement to Sell Sierra Scientific Instruments to Given Imaging
4. 4-Star General-Former U.S. Drug Czar Barry McCaffrey Featured At Tacoma Treatment Solutions 5-Year Anniv: Mon. May 24, 11 a.m., 9500 Front Street, Lakewood WA 98499
5. Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC
6. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
7. ADVENTRX to Present at the Wall Street Analyst Forum 21st Annual Institutional Investor Conference on November 11
8. Water Street Healthcare Partners Acquires OraPharma, Inc.
9. TPI 2010 Shareholder Annual Meeting on 3/21/11 to Be Held at 100 Wall Street, near NYSE
10. Water Street Healthcare Partners Acquires MarketLab, Inc.
11. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants totaling ... as part of its prestigious Bayer Hemophilia Awards Program (BHAP). ... Philadelphia and Uniformed Services University of ... among the winners. Grant recipients were announced last night during ... (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... of Echenberg Institute, is announcing a new safe and effective at-home VuVa ... other painful pelvic pain conditions such as pelvic floor dysfunction, vulvodynia, vulvar ... ... VuVa ... company, VuVatech LLC, fills a void in the women,s wellness market because ...
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... 27, 2017 , ... GAFFEY Healthcare, a leading provider of ... to Vice President of Revenue Cycle Business Services and Suzanne Dusak to Vice ... executive officer (CEO). , Elrene has been with company since Oct 2014 and ...
(Date:7/27/2017)... , ... July 27, 2017 , ... Team Novo Nordisk, ... Brand to the men’s pro squad as a stagiaire for the remainder of the ... professional debut on July 31st at the Tour of Utah. , “Every season we ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley D. ... advancement in drug therapy for patients living with relapsing and primary multiple sclerosis ... B cell targeted therapy that has been proven to significantly reduce signs of ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we ... from San Jose, Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending ... orthodontic braces. In doing so, it offers an effective alternative to traditional braces. As ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... “We are ... offer the ability for patients to schedule an appointment online in real time,” said ... the Six Month Smiles provider directory will bring more Six Month Smiles patients to ...
Breaking Medicine News(10 mins):